Physician profile
Derek Bowman
NPI 1942921663
$3,041.98
in general payments reported to CMS, 2019-2025
34 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $98.70 · 2023: $778 · 2024: $1,005 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,934.83 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $551.26 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $407.05 | 2023-2025 | |
| Pfizer INC. | $334.63 | 2023-2025 | |
| Lilly USA, LLC | $206.52 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $148.21 | 2023-2025 | Bexsero, Shingrix, Arexvy |
| Dexcom, INC. | $128.68 | 2022-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $112.12 | 2023-2024 | Accrufer |
| Amgen INC. | $97.61 | 2023-2025 | Otezla, Repatha, Repatha |
| Aimmune Therapeutics, INC. | $86.14 | 2024-2025 | Zenpep |
| Sanofi Pasteur INC. | $83.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $75.85 | 2023-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $74.91 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.80 | 2023-2025 | Stiolto Respimat, Jardiance, Spiriva Respimat |
| Exact Sciences Corporation | $70.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $66.58 | 2023-2025 | Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56.39 | 2023-2024 | Airsupra, Farxiga |
| Xeris Pharmaceuticals, INC. | $47.48 | 2023-2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $42.39 | 2025 | Inspire |
| Vertex Pharmaceuticals Incorporated | $33.44 | 2025 | |
| Phathom Pharmaceuticals, INC. | $33.35 | 2024-2025 | Voquezna |
| Tonix Medicines, INC. | $31.25 | 2025 | Tonmya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.06 | 2023 | Xifaxan, Trulance |
| Abbott Laboratories | $30.20 | 2024-2025 | Freestyle Libre 3 |
| Indivior INC. | $29.38 | 2023 | Sublocade |
| Janssen Biotech, INC. | $28.07 | 2025 | Tremfya |
| Corcept Therapeutics | $26.21 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.13 | 2025 | Dupixent |
| Boston Scientific Corporation | $20.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.10 | 2023 | |
| Eisai INC. | $17.14 | 2024 | |
| Horizon Therapeutics Plc | $14.76 | 2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $14.70 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $14.61 | 2023 | |
| Alkermes, INC. | $14.04 | 2023 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.